Spectral AI algorithms beat physicians in burn tissue assessments

The company plans to file the results with the FDA by mid-2025 and launch the product in 2026.

By Nick Paul Taylor • March 18, 2025

Labcorp to buy Opko unit’s cancer test assets for up to $225M

Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth testing areas.

By Susan Kelly • March 12, 2025

CAP urges HHS to revoke lab developed test rule, citing Trump order

The pathologists group wants the regulation terminated in light of an executive order from President Trump that calls for federal agencies to “alleviate unnecessary regulatory burdens.”

By Nick Paul Taylor • Feb. 26, 2025

Thermo Fisher to buy Solventum’s purification and filtration unit for $4.1B

Wall Street applauded the deal, sending shares of Solventum, the 3M spinoff, up 10% on Tuesday.

By Susan Kelly • Feb. 25, 2025

Quest to buy Fresenius Medical Care kidney testing assets

The acquisition will add dialysis-related water testing to Quest’s portfolio and position the company to perform the tests and other end-stage kidney disease services for Fresenius Medical Care.

By Nick Paul Taylor • Feb. 25, 2025

Guardant accuses Natera of poaching employees, stealing trade secrets

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position in the early cancer test industry.”

By Nick Paul Taylor • Updated Feb. 25, 2025

GE Healthcare invests $138M to expand contrast media production at Ireland site

The new facility will enable production of 25 million more patient doses per year by the end of 2027.

By Nick Paul Taylor • Feb. 4, 2025

23andMe considers sale as cash runs low

The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.

By Nick Paul Taylor • Jan. 30, 2025

Neko Health raises $260M to expand body scan service, fund R&D

The company uses various medical devices to noninvasively check moles, the heart and more.

By Nick Paul Taylor • Jan. 28, 2025

Illumina, Nvidia team to use AI in foundation models

Nvidia’s partnership with the gene sequencing company is one of several healthcare collaborations revealed Monday by the computing giant.

By Susan Kelly • Jan. 13, 2025

EU medtech regulations reducing options for patients, companies say

Stakeholders branded the MDR and IVDR rules “unreasonably complicated,” “terrible for EU patients and doctors” and “a mess.”

By Nick Paul Taylor • Jan. 13, 2025

Top 10 medtech deals of 2024

Multibillion-dollar buyouts returned last year, led by Johnson & Johnson’s $13.1 billion acquisition of Shockwave Medical.

By Nick Paul Taylor • Jan. 2, 2025

Labcorp closes takeover of Ballad Health outreach laboratory services

Labcorp continued its streak of hospital lab purchases with a deal that will expand its testing capabilities to communities in Tennessee, Virginia, North Carolina and Kentucky.

By Nick Paul Taylor • Dec. 12, 2024

Guardant awarded nearly $293M in false ad trial against Natera

Natera allegedly made “false and misleading statements” to convince people to use its Signatera cancer test rather than Guardant’s rival product Reveal.

By Nick Paul Taylor • Dec. 2, 2024

Medtronic wins VA contract to install AI-powered endoscopy units

The three-year contract expands Medtronic’s work with the VA to cover the installation of almost 100 more GI Genius endoscopy modules at U.S. centers.

By Nick Paul Taylor • Nov. 26, 2024

Labcorp hires Julia Wang as CFO

Wang will replace Glenn Eisenberg, who is retiring after 10 years in the role. Evercore analysts called Eisenberg a Labcorp “institution.”

By Susan Kelly • Nov. 20, 2024

GE Healthcare’s head-only MRI scanner cleared by the FDA

The system is designed to shorten scan times, which may be better for people who struggle to stay still or have claustrophobia, and to detect more subtle abnormalities.

By Nick Paul Taylor • Nov. 14, 2024

23andMe to lay off more than 200 employees amid business struggles

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”

By Ricky Zipp • Nov. 13, 2024

Advamed CEO congratulates Trump, stresses need for public policy support

Donald Trump’s election victory comes weeks after the FDA named a new leader for the medical device center and as the agency’s contentious LDT final rule is challenged in court.

By Ricky Zipp • Nov. 11, 2024

Exact Sciences’ forecast cut shocks analysts

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday.

By Nick Paul Taylor • Nov. 8, 2024

Tempus AI to buy genetic testing company for $600M

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing business.

By Elise Reuter • Nov. 6, 2024

Advamed asks CMS to cover extra imaging of dense breast tissue

Many patients with dense breast tissue currently have to pay out of pocket or forgo potentially life-saving additional testing, Advamed said in a letter.

By Nick Paul Taylor • Nov. 6, 2024

European Parliament calls for proposals to reform MDR and IVDR by end of Q1

Parliament asked the European Commission to publish acts that address the “most pressing challenges and bottlenecks” of the regulations and propose the “systematic revision” of the legislation.

By Nick Paul Taylor • Oct. 24, 2024

Medtech Conference recap: New CDRH leader details approach; AI and LDTs in focus

Catch up on our recent coverage of Advamed’s The Medtech Conference.

By Elise Reuter • Oct. 23, 2024

GE Healthcare opens AI Innovation Lab to grow new projects

The AI Innovation Lab is designed to accelerate early concept artificial intelligence projects including tools to predict the recurrence of cancer and automate image interpretation.

By Nick Paul Taylor • Oct. 22, 2024